An Early Phase 1 interventional study of Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1 in Retinal Edema, sponsored by Tanta University. Not yet recruiting at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2024-03-05.
Sponsored by Tanta University · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Prospective interventional study on 60 eyes of resistant diabetic macular edema and central retinal vein occlusion that will receive suprachoroidal injection of Triamcinolone Acetonide (SCTA).
Patients fulfilling one or more of the following criteria will be considered to have resistant diabetic macular edema (DME) after at least 3 consecutive monthly anti vascular endothelial growth factor (VEGF) injections in the previous 6 months: central macular thickness greater than 300 μm by spectral-domain optical coherence tomography (SD-OCT), reduction of retinal thickness by less than 10% of baseline retinal thickness, or suboptimal visual improvement (failure to gain at least 3 lines on the Snellen chart).
The subjects included in the research will undergo the following tests and investigations:
Exclusion criteria will be:
Injection technique:
Preoperative preparation:
All patients were dilated before suprachoroidal injection of Triamcinolone Acetonide (SCTA) and indirect ophthalmoscope was placed at hand to examine fundus after injection.
We used 30 gauge 1cc insulin syringe. Other dispensable included 24 gauge intravenous branula. Needle was withdrawn from branula and branula was cut in such a way that only 1000um of insulin syringe was exposed from the edge of branula. 0.1 ml (4 mg ) of Triamcinolone Acetonide (TAAC) will be injected.
Post operative care:
After the injection topical antibiotic drop was applied (Moxifloxacin hydrochloride 0.5% Vigamox, Alcon, USA) and the eye was patched for several hours.
After surgery patients were instructed to administer antibiotic drop four times daily for 3 days .
Privacy of the patients must be guaranteed ,the data acquired from the participants will stay confidential through:
Medical care will be carried out to complications like syncope, subconjunctival hemorrhage and surgical treatment by pars plana vitrectomy will be done in case of occurrence of vitreous hemorrhage, retinal detachment or endophthalmitis.
29 studies on the registry are indexed under Papilledema; 7 are open to participants now.
This study's planned enrollment of 100 is above the median of 50 across 19 interventional studies indexed under Papilledema.
Browse Papilledema studies →Tanta University is the lead sponsor of 1,015 studies on the registry; 321 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
* Prospective non randomized interventional study on 60 eyes of 40 patients with previously diagnosed macular edema secondary to type 1 or 2 diabetes mellitus will be included. * The study will be conducted from January 2021 to June 2021. * For transition to suprachoroidal injection of TAAC a diagnosis of resistant DME is required. Cases with recent onset central retinal vein occlusion less than 2 months duration will be included
Drug: Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1
Drug page: Triamcinolone AcetonideStudies of Triamcinolone AcetonideTriamcinolone Acetonide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
suprachoroidal injection of the drug in cases of resistant diabetic macular edema and central retinal vein occlusion
Also known as: 30 gauge syringe with 24 gauge cannula
Improvement of central macular thickness
Reduction of the central macular thickness below 300 um
Time frame: 1 month
improved vision
Improvement of best corrected visual acuity
Time frame: 3 months
Plan to share: No
Start is estimated for Dec 2024; primary completion for Dec 2024, 0 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Triamcinolone Acetonide